Burrill & Company was retained by Procter & Gamble (P&G) to assist in forming an alliance with Taiwan-based TaiGen Biotechnology Co., Ltd., involving P&G's Phase I non-fluorinated quinolone antibiotic. Although this antibiotic is a strong development candidate, anti-infectives are not a focus of P&G's internal business, so P&G decided to look outside for a development partner. With the help of BGC, P&G found Taigen, which has been trying to enhance its pre-clinical pipeline and accelerate its push into Mainland China. Burrill & Company successfully helped the two companies form an alliance in which TaiGen will be responsible for conducting the Phase Ib and Phase II development of the compound. If the Phase II results are positive, P&G, in conjunction with TaiGen, may then seek a pharmaceutical partner for Phase III development and subsequent commercialization of the compound. Moreover, TaiGen acquired the development and commercialization rights within China, Taiwan, Korea and the ASEAN countries.